Due to the current pandemic, many pharmaceutical companies are listing their stocks in the market. It helps them to raise money in order to meet medical demands and to conduct research.
The majority of these companies are using millions of dollars to research a possible covid-19 treatment. While some companies have been successful, others have incurred losses.
The news about possible Covid-19 research is enough to gain investor’s interest. Most of the investors are purchasing the stocks on new pharma companies with Covid-19 connection.
It helps them to invest money at the right time and make tremendous profits in the future. One such company is Valneva. The stocks of this company NASDAQ VALN at https://www.webull.com/quote/nasdaq-valn have become the talk of the town.
What is Valneva?
It is a vaccine company that helps to develop an advanced vaccine for making our lives better. They are into development as well as selling vaccines.
They develop prophylactic vaccines to fight deadly and viruses and infections. Currently, many vaccines are in the development stage.
This French biotech company is also developing a vaccine for Covid-19 infection. The headquarters of this company is in Saint-Herblain. They have many sites in France, the US and Canada, where they develop and manufacture vaccines.
This company was established in the year 2013. It was a result of a merger between Vivalis SA and Intercell. This company is already listed on Euronext Paris.
It was previously listed on Vienna Stock Exchange as well. However, as the company is becoming popular these days, they have listed it on NASDAQ as well. Now, you can easily invest in NASDAQ VALN.
What Do They Do?
This vaccine making company develops as well as commercialize vaccines. They have products as Ixiaro in the market. It helps to fight against Japanese encephalitis.
They have also developed Dukoral. It helps to fight against cholera. Apart from these approved vaccines, several other vaccines are under development.
Currently, they are working on four vaccines. They are developing a vaccine against Chikungunya. They are also developing a vaccine against Lyme disease. The name of the vaccine is VLA15. It will be launched in 2024.
They are also developing a vaccine for the Zika virus. Apart from these vaccines, they are also developing a vaccine for Covid-19. They have patterned with Dynavax technologies to develop VLA2001.
Currently, the vaccine is under the trial phase. They are going to test it on 150 people. Due to this move, the company have gained the attention of many investors. NASDAQ VALN is performing better than most of the biotech stocks like nasdaq hofv at https://www.webull.com/quote/nasdaq-hofv in the market.